Haass lab (@haass_lab) 's Twitter Profile
Haass lab

@haass_lab

The Haass lab Twitter account | šŸ‡©šŸ‡Ŗ @DZNE_de @SyNergy_Cluster | šŸ”¬AD, FTLD & microglia research | šŸ•µļø PI Christian Haass (signed -CH) | šŸ’¬ Tweets by @LisdeW_

ID: 1367445293277577216

linkhttps://www.biochemie.abi.med.uni-muenchen.de/index.html calendar_today04-03-2021 12:02:28

209 Tweet

1,1K Followers

282 Following

Dieter Edbauer (@dieter_edbauer) 's Twitter Profile Photo

Interested in translational science? 🧪 Our team at #DZNE Munich is seeking a technician for the GA-VAX project. Your work could directly contribute to clinical trials with #C9orf72 #ALS patients. Apply now and join our team! #Jobs #Research jobs.dzne.de/de/jobs/101347…

Hector Fellow Academy (@hfa_academy) 's Twitter Profile Photo

Big announcement today!šŸ“¢ We are very pleased to present the new video portrait with Hector Fellow Prof. Dr. Dr. h.c. Christian Haass and his research on Alzheimer's disease.šŸ‘‰youtube.com/watch?v=tHhVov……… #HFA #videoportrait #alzheimersdisease #alzheimersresearch #cellbiology

RikOssenkoppele (@rikossenkoppele) 's Twitter Profile Photo

Homozygosity for R47H in TREM2 and the Risk of Alzheimer’s Disease Another AD-relevant publication NEJM this week. TREM2 variants like R47H may induce partial loss of function by interfering with binding of ligands such as low-density lipoprotein (LDL), apolipoprotein E

Homozygosity for R47H in TREM2 and the Risk of Alzheimer’s Disease

Another AD-relevant publication <a href="/NEJM/">NEJM</a> this week.

TREM2 variants like R47H may induce partial loss of function by interfering with binding of ligands such as low-density lipoprotein (LDL), apolipoprotein E
Molecular Neurodegeneration (@molneuro) 's Twitter Profile Photo

'Mis-localization of endogenous #TDP43 leads to #ALS-like early-stage metabolic dysfunction and progressive motor deficits' Yiying Hu, Alexander Hruscha, Chenchen Pan...Bettina Schmid @DZNE_en @SyNergy_Cluster bit.ly/45vRfEk

'Mis-localization of endogenous #TDP43 leads to #ALS-like early-stage metabolic dysfunction and progressive motor deficits'

Yiying Hu, Alexander Hruscha, Chenchen Pan...Bettina Schmid @DZNE_en @SyNergy_Cluster

bit.ly/45vRfEk
RikOssenkoppele (@rikossenkoppele) 's Twitter Profile Photo

Nick Fox making the case that excess brain volume loss associated with Lecanemab (or other effective mAB’s) is associated with the removal of ā€œspace-occupyingā€ structures, as amyloid plaques occupy ~6-8% of the cortex in autopsy studies. #AAIC24

Nick Fox making the case that excess brain volume loss associated with Lecanemab (or other effective mAB’s) is associated with the removal of ā€œspace-occupyingā€ structures, as amyloid plaques occupy ~6-8% of the cortex in autopsy studies. #AAIC24
Helmholtz (@helmholtz_de) 's Twitter Profile Photo

Wir sprechen in der neuesten Resonator-Podcastfolge über den aktuellen Stand der Alzheimerforschung. Zu Gast ist Christian Haas vom @DZNE_de und es geht auch um neue Medikamente. Ganze Sendung: resonator-podcast.de/2024/res207-zu… #Alzheimer #DZNE #Lecanemab #Podcast

MatthiasBrendel (@matbrendel) 's Twitter Profile Photo

🚨 Just out in Theranostics: ā˜¢ļø we developed a new microglia specific Cu64-labeled TREM2-PET radiotracer ā˜¢ļø importantly this antibody based tracer has an integrated brain shuttle system (hTfR) to cross the blood-brain barrier. thno.org/v14p6319.htm #Theranostics

Lena Spieth (@lenaspieth) 's Twitter Profile Photo

🚨NEW PAPER ALERT 🚨 Our paper just got published in Immunity ! From Munich with 🄨 Check it out here: cell.com/immunity/fullt… Seiji Kaji, Stefan Berghoff, Mikael Simons #apoe #Alzheimers #microglia 1/9

EU Medicines Agency (@ema_news) 's Twitter Profile Photo

šŸ“¢The CHMP recommends authorising a new treatment for early #AlzheimersDisease in the EU. Leqembi is intended for treatment of mild dementia and cognitive impairment in a restricted patient population with a specific genetic make-up. šŸ‘‰ ema.europa.eu/en/news/leqemb…

šŸ“¢The CHMP recommends authorising a new treatment for early #AlzheimersDisease in the EU. 

Leqembi is intended for treatment of mild dementia and cognitive impairment in a restricted patient population with a specific genetic make-up. 

šŸ‘‰ ema.europa.eu/en/news/leqemb…